Bloomberg ID:  CCSC130 <Equity>       Morningstar ID:  F00000V3XE

Strategy Objective

Junior Biotech+ is a passively managed strategy that aims to match the returns of Biotechnology, Life Sciences and Medical Device stocks that are within five years of their Initial Public Offering. The strategy invests worldwide.



Biotech+ stocks have excellent growth potential, buoyed by new discoveries. These publicly traded stocks are highly levered to the success of their drugs and devices undergoing clinical trials. We believe that younger companies are more likely to be using newer technology and have a higher probability of success.

* Live Inception Date: January 01, 2021;
   backtest prior to Inception Date.

Performance Summary Backtest to February 28, 2021, Net of Fees and Trading Costs

Constantia Logo-white-04.png

Constantia Capital, LLC

17 Hendrickson Rd, Suite 100
Lawrenceville, NJ 08648



  • LinkedIn Social Icon

Content © 2013-2021 Constantia Capital, LLC.  All rights reserved.  Registered in New Jersey, New York, and Pennsylvania.
Past performance is not a guarantee of future results.  Strategies involve risk of loss of principal.